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Miltefosine is an alkyl phosphocholine with good oral bioavailability and in vitro activity against Cryptococcus species that has
gained interest as an additional agent for cryptococcal infections. Our objective was to further evaluate the in vivo efficacy of
miltefosine in experimental in vivomodels of cryptococcal meningoencephalitis and disseminated cryptococcosis. Mice were
infected intracranially or intravenously with either C. neoformansUSC1597 or H99. Miltefosine treatment (1.8 to 45 mg/kg of
body weight orally once daily) began at either 1 h or 1 day postinoculation. Fluconazole (10 mg/kg orally twice daily) or ampho-
tericin B deoxycholate (3 mg/kg intraperitoneally once daily) served as positive controls. In our standard models, miltefosine did
not result in significant improvements in survival or reductions in fungal burden against either C. neoformans isolate. There was
a trend toward improved survival with miltefosine at 7.2 mg/kg against disseminated cryptococcosis with the H99 strain but only
at a low infecting inoculum. In contrast, both fluconazole and amphotericin B significantly improved survival in mice with cryp-
tococcal meningoencephalitis and disseminated cryptococcosis due to USC1597. Amphotericin B also improved survival against
both cryptococcal infections caused by H99. Combination therapy with miltefosine demonstrated neither synergy nor antago-
nism in both models. These results demonstrate limited efficacy of miltefosine and suggest caution with the potential use of this
agent for the treatment of C. neoformans infections.
Cryptococcal meningoencephalitis remains a substantial infec-tious disease challenge. Populations at risk for infections
caused by Cryptococcus neoformans include HIV/AIDS patients,
recipients of solid organ or hematopoietic stem cells transplants,
as well as those receiving high-dose chemotherapy or those having
some other immunocompromised condition (1, 2). The Centers
for Disease Control and Prevention have estimated that in HIV/
AIDS patients the global burden of cryptococcosis is 1 million
cases annually (3), while other studies have reported the 3-month
mortality for the treatment of acute cryptococcal meningoen-
cephalitis to be approximately 20% (4, 5). Effective treatment is
available in the United States and other developed countries and
includes amphotericin B and flucytosine as induction therapy fol-
lowed by fluconazole (2). However, intravenous medications as
well as oral flucytosine may not be available in less-developed
areas, and the use of high-dose oral fluconazole is not as effective
as induction therapy with amphotericin B (6, 7). Thus, there is a
clinical need for new or alternative strategies, including agents
that may be administered orally, for the treatment of cryptococcal
meningoencephalitis.
Miltefosine (hexadecylphosphocholine) is an alkyl phos-
phocholine that has been used in the treatment of leishmania-
sis, including New World cutaneous, mucocutaneous, and vis-
ceral disease (8–15). Miltefosine can be administered by
mouth, and good oral bioavailability (82 to 94%) has been
reported in rats and dogs (16). Recently, this agent has gained
interest as a potent therapeutic against invasive mycoses, in-
cluding cryptococcal infections as in vitro studies have demon-
strated potent activity against C. neoformans and dermato-
phytes (17, 18). In one case report, miltefosine in combination
with voriconazole and terbinafine was successfully used to treat
a child with Scedosporium prolificans osteomyelitis (19). Im-
provements in survival and reductions in tissue fungal burden
with the oral administration of miltefosine were also reported
in a murine model of disseminated cryptococcosis (18). Based
on the preliminary in vitro data that demonstrated activity
against C. neoformans and in vivo efficacy against disseminated
cryptococcosis, we sought to further evaluate the effectiveness
of miltefosine in our murine model of cryptococcal meningo-
encephalitis, both as monotherapy and in combination with
other antifungals. Studies were also conducted to further char-
acterize the efficacy of this agent against disseminated crypto-
coccosis.
MATERIALS AND METHODS
Isolates and antifungal agents. Cryptococcus neoformans clinical isolates
USC1597 and H99 were used throughout this study. Each isolate was
subcultured at least twice on Sabourauddextrose agar (SDA) (Remel, Inc.,
Lenexa, KS) before each in vitro and in vivo experiment. Prior to inocula-
tion, the isolates were grown in brain heart infusion broth overnight at
37°C with shaking. The cells were then collected by centrifugation and
were washed three times in sterile saline. The inoculum concentrations
were determined with a hemocytometer, and viability was confirmed by
plating serial dilutions and enumeration of CFU. The clinically available
intravenous formulations of fluconazole (Pfizer, Inc., New York, NY) and
amphotericin B deoxycholate (X-Gen Pharmaceuticals, Big Flats, NY)
were used in all studies and were prepared according to the package in-
serts. Miltefosine powder was obtained from Cayman Chemical Com-
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pany (Ann Arbor, MI) and was dissolved in physiologic saline prior to
each experiment.
Susceptibility testing. Susceptibility testing was done by broth mi-
crodilution in accordance with the CLSI M27-A3 methodology in RPMI
1640 growthmedium buffered with 0.165Mmorpholinepropanesulfonic
acid (MOPS; pH 7.0) (20). Stock solutions were prepared in water (flu-
conazole and amphotericin B deoxycholate) or RPMI 1640 medium
(miltefosine). Aliquots of each agent (0.1 ml) at 2 concentrations were
dispensed into 96-well microdilution trays. C. neoformans cells in RPMI
mediumwere added (final inoculum, 0.5 103 to 2.5 103 cells/ml), and
the trays were incubated at 35°C. Final antifungal concentrations ranged
from 0.125 to 64 g/ml for miltefosine and fluconazole and from 0.03 to
16g/ml for amphotericin B. TheMICs for fluconazole were read at 50%
reduction in turbidity compared to growth of the control at 72 h. For
amphotericin B and miltefosine, MICs were determined as 100% inhibi-
tion relative to growth of the controls. In later experiments, 5% (50 mg/
ml) bovine serum albumin (BSA; Equitech Bio, Inc. Kerrville, TX) was
added to the RPMImedium to assess the effects of protein binding on the
in vitro potency of miltefosine.
Animal model. Previously described murine models of cryptococcal
meningoencephalitis and disseminated cryptococcosis were utilized for
all studies (18, 21–23). Immunocompetent outbred ICR mice (Harlan)
weighing approximately 25 g were housed five mice per cage and had
access to food and water ad libitum. To establish cryptococcal meningo-
encephalitis, mice were anesthetized using isoflurane, and C. neoformans
at 1,500 to 2,600 cells/mouse was delivered in a 0.06-ml volume through a
27-gauge needle fastened to a tuberculin syringe with a cuff to prevent
penetration of more than 1 mm. A midline puncture through the cranial
vault approximately 6 mm posterior to the orbit was made, and the inoc-
ulum was injected, after which the mice were allowed to recover. To es-
tablish disseminated cryptococcosis, mice were inoculated intravenously
via the lateral tail vein with C. neoformans over a range of inocula in
different experiments (4.0 103 to 6.1 105 cells/mouse) delivered in a
0.2-ml volume of sterile saline. This study was approved by the Institu-
tional Animal Care and Use Committee at the University of Texas (UT)
Health Science Center at San Antonio, and all animals weremaintained in
accordance with the American Association for Accreditation of Labora-
tory Animal Care (24).
Antifungal treatment. Antifungal therapy with miltefosine was initi-
ated either 1 h or 1 day postinoculation at doses ranging between 1.8 and
60 mg/kg of body weight once daily by oral gavage. Amphotericin B was
initiated at either 1 h or 1 day postinoculation at a dose of 3 mg/kg once
daily by intraperitoneal injection, while fluconazole was initiated at 1 day
postinoculation in all experiments at a dose of 10mg/kg once daily by oral
gavage. Between 8 and 20 mice were included per dosage group of each
antifungal in each experiment. The duration of therapy for each agent in
each study is specified in Results.
Outcome measures. Survival and brain tissue fungal burden were
used to measure the in vivo efficacy of antifungal therapy. In the survival
experiments, mice were followed off therapy to either day 21 or day 30
postinoculation, and any animal that appeared moribund was humanely
euthanized. In tissue burden experiments, brain tissues were aseptically
collected 1 day after treatment stopped in order tomeasure fungal burden.
Brains were weighed and then homogenized in sterile saline with a tissue
homogenizer. Serial dilutionswere prepared in sterile saline and plated on
SDA. After 48 to 72 h of incubation, colonies were counted, and the
number of CFU per gram of tissue for each animal was calculated.
Statistics. Survival was plotted by Kaplan-Meier analysis, and log rank
and Fisher’s exact tests were used to assess for significant differences in
median survival and percent survival, respectively. Differences in tissue
fungal burden were assessed using analysis of variance (ANOVA) with
Tukey’s posttest for multiple comparisons. A P value of 0.05 was con-
sidered statistically significant.
RESULTS
Susceptibility. Miltefosine demonstrated in vitro activity against
C. neoformans USC1597 and H99 (MICs of 1 g/ml and 0.5 g/
ml, respectively) in RPMImedium. Fluconazole was active against
each C. neoformans isolate (MIC against USC1597, 1 g/ml; MIC
against H99, 2 g/ml), and amphotericin B also demonstrated
potent activity against both isolates (MIC of 0.25 g/ml). In con-
trast to the activity observed in RPMImedium formiltefosine, the
potency of this agent was significantly reduced with the addition
of 5% BSA (MIC of64 g/ml).
Cryptococcal meningoencephalitis caused byC. neoformans
USC1597. The objective of this study was to evaluate the in vivo
efficacy of miltefosine against cryptococcal meningoencephalitis,
and the initial experiments utilized a fully susceptible C. neofor-
mans isolate (USC1597) to establish infection. Monotherapy with
miltefosine at doses ranging from 5 to 60 mg/kg/day, amphoteri-
cin B at 3 mg/kg/day, or fluconazole at 10 mg/kg twice daily was
initiated at 1 day postchallenge, and each agent was continued for
10 days in the survival arm and for 7 days in the fungal burden
arm. Miltefosine did not lead to a survival advantage at doses as
high as 45 mg/kg as the median survival (range, 13.5 to 23.5 days)
and percent survival (0 to 10%) at each dose did not differ signif-
icantly from rates for untreated controls (19 days and 10.5%, re-
spectively) (Fig. 1A and B). In contrast, median survival was sig-
nificantly prolongedwith fluconazole and amphotericin B (29 and
30 days, respectively) compared to controls and each miltefos-
ine dose (P 0.05 for all comparisons). In addition, amphotericin
B significantly improved the percentage of animals surviving to
day 30 (95%; P  0.05) (Fig. 1B). Although therapy with milte-
fosine at 60 mg/kg was initially tried, mice were unable to tolerate
a dose this high as several died following a single administration;
therefore, this dose was discontinued. Combination therapy with
miltefosine was also ineffective. Neither a survival advantage nor
disadvantage was observed with miltefosine at 45 mg/kg plus am-
photericin B or fluconazole as the median and percent survival
values for these combinations were similar to those observed with
monotherapy with these antifungals (Fig. 1C).
Since the marked survival advantage observed with daily ad-
ministration of amphotericin B may have masked any benefit of
combination therapy, we also evaluated daily high-dose miltefos-
ine with a short course of this polyene. In this experiment, both
miltefosine at 45 mg/kg and amphotericin B were initiated at 1 h
postchallenge, and amphotericin B was discontinued after two
doses. Even when therapy was initiated shortly after intracranial
challenge, no improvement in survival was observed with milte-
fosine monotherapy as the median and percent survival values
(17.5 days and 0%, respectively) were similar to those of untreated
controls (15.5 days and 0%, respectively) (Fig. 1D). In contrast,
monotherapy with a short course of amphotericin B still resulted
in longer survival than that of controls and miltefosine treatment
(24 days; P  0.01). Similar to the previous results, miltefosine
combination therapy did not lead to a significant benefit com-
pared to amphotericin B alone (median survival, 21.5 days). The
lack of efficacy of miltefosine was also evident in the brain tissue
fungal burden results (Table 1). No reductions in fungal burden
were observed in any miltefosine monotherapy group compared
to burden in untreated controls. In contrast, significant reduc-
tions were observed in mice that received fluconazole or ampho-
tericin B as well as in those that received combination therapy.
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Furthermore, the addition of miltefosine did not result in further
reductions in fungal burden compared to treatment with flucona-
zole or amphotericin B alone.
Cryptococcal meningoencephalitis caused byC. neoformans
H99. Since the previous study that reported in vivo efficacy of
miltefosine against disseminated cryptococcosis used a different
C. neoformans strain (H99), we also evaluated the effectiveness of
this agent against cryptococcal meningoencephalitis caused by
this isolate. As shown in Fig. 2, miltefosine was also ineffective
against central nervous system (CNS) infection caused by H99.
No improvements in survival were observedwhenmiltefosinewas
initiated 1 h after inoculation at lower doses (1.8 to 7.2 mg/kg/day
throughday 4) (Fig. 2A) orwhenhigher doseswith a longer period
of administration were used (15 and 45 mg/kg/day through day
10) (Fig. 2B). In contrast, treatmentwith both amphotericin B and
fluconazole resulted in significant improvements in survival (me-
dian survival, 21 and30 days, respectively) (Fig. 2C) compared
to survival of untreated controls (18 days; P  0.05) and each
miltefosine dose (range, 11.5 to 16.5 days; P 0.0001). The per-
centage of animals surviving to day 30was also significantly higher
in animals treated with amphotericin B than for all other groups
(70% versus 0%; P 0.001).
FIG 1 Survival curves in mice inoculated intracranially with C. neoformans USC1597 at 1,900 to 2,800 CFU/animal. Antifungal monotherapy therapy with
miltefosine (MTF), fluconazole (FLC), or amphotericin B (AMB) or combination therapy began at 1 day postchallenge (A, B, and C) and continued for 10 days
(n 19 to 20 mice per group for untreated controls, fluconazole, and amphotericin B and 8 to 10 mice per miltefosine dose). The early initiation of miltefosine
and amphotericin B or combination therapy at 1 h postchallenge was also evaluated (D). Daily miltefosine therapy continued for 10 days, and amphotericin B
was administered for only two doses (n 9 to 10mice per group). *,P 0.05 formedian survival compared to untreated controls; §,P 0.05 for percent survival
at study endpoint compared to untreated controls.
TABLE 1 Fungal burden in the brains or lungs of mice with cryptococcal meningoencephalitis or disseminated cryptococcosis following intracranial
or intravenous inoculation with C. neoformans USC1597
Inoculation method
and tissue
C. neoformans USC1597 fungal burden (log10 CFU/gram) by treatment
a
Control
MTF (mg/kg)
FLC AMB
MTF (45
mg/kg)
FLC
MTF (45 mg/
kg) AMB5 10 15 45
Intracranialb
Brain 6.04 0.51 5.57 0.35 5.98 0.51 5.61 0.54 6.03 0.42 2.64 1.05* 2.20 0.92* 3.32 0.90* 2.83 1.32*
Intravenousc
Lung 7.22 0.62 7.46 0.28 5.77 1.99** 5.67 1.61**
Brain 6.23 0.23 6.34 0.15 4.35 1.20* 4.04 1.02*
a MTF, miltefosine; FLC, fluconazole; AMB, amphotericin B. Values are means standard deviations. Fluconazole was administered at 10 mg/kg, and amphotericin B was
administered at 3 mg/kg. * P 0.001; **, P 0.05 (versus untreated controls and all-miltefosine monotherapy).
b In the cryptococcal meningoencephalitis model, antifungal therapy with miltefosine, fluconazole, or amphotericin B was continued through day 7, and brains were collected on
day 8 for fungal burden quantification (n 19 to 20 mice per group for untreated controls, fluconazole, and amphotericin B and 8 to 10 mice per miltefosine dose).
c In the disseminated cryptococcosis model, miltefosine therapy was continued through day 7 while amphotericin B was administered for two doses. The lungs and brains were
collected on day 8 for fungal burden quantification (n 10 mice per group).
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Disseminated cryptococcosis caused by C. neoformans
USC1597 and H99. We also evaluated the efficacy of miltefosine
for the treatment of disseminated cryptococcosis following intra-
venous challenge. In these experiments, miltefosine (1.8 to 45mg/
kg/day) was initiated 1 h after inoculation, while fluconazole and
amphotericin B were started 1 day after infection. As seen against
cryptococcal meningoencephalitis, miltefosine did not improve
survival at any dose tested (median survival range, 10 to 14 days)
compared to rates for untreated controls (12 days) (Fig. 3A andB).
Survival was significantly improved with fluconazole and ampho-
tericin B (21 days for both agents; P  0.0001). Combination
therapy also did not significantly improve survival compared to
treatment with amphotericin B alone (Fig. 3C). Furthermore, no
significant reductions in fungal burden were observed within the
lungs or brain tissue with high-dose miltefosine (45 mg/kg) as
monotherapy (Table 1), nor did combination therapy result in
further reductions in fungal burden compared to amphotericin B
monotherapy.
We also tested the effectiveness of miltefosine against dissem-
inated cryptococcosis caused by C. neoformans H99. As shown in
Fig. 4, miltefosine and fluconazole did not improve survival com-
pared to survival of untreated controls, while amphotericin B sig-
nificantly improved survival versus all other groups. As these re-
sults were in contrast to what was previously reported in a similar
model of disseminated cryptococcosis, we also evaluated the ef-
fects of different infecting inoculum levels on the survival of un-
treated controls. As expected, the higher inocula (4.7  104 and
5.9 105 cells/mouse) resulted in 100%mortality early during the
course of infection (Fig. 5A). As the survival curve for the inocu-
lum of 4.8 103 cells/mouse was similar to that observed in un-
treated controls in the previous study that reported in vivo efficacy
formiltefosine (18), we also tested the effectiveness of this agent at
this lower infecting inoculum. Interestingly, a trend toward im-
proved survival was observed with miltefosine at 7.2 mg/kg/day
versus survival of untreated controls (17.5 versus 20.5 days, re-
spectively; P  0.09), which was in agreement with the results of
the previous study. This suggests that the in vivo efficacy of this
agent may be inoculum dependent.
DISCUSSION
Miltefosine, an alkyl phosphocholine, has been used as therapy for
various forms of leishmaniasis and has recently garnered attention
for its potential use against invasive fungal infections, including
cryptococcosis. Current interest in this agent is due to the in vitro
activity against Cryptococcus species and dermatophytes and the
clinical success thatwas reported in one patient treatedwithmilte-
fosine in combination with other antifungal agents for Scedospo-
rium prolificans osteomyelitis (17, 19). Additionally, studies have
also reported in vivo efficacy of miltefosinemonotherapy in amu-
rine model of disseminated cryptococcosis as well as meningitis
FIG 2 Survival curves of mice inoculated intracranially with C. neoformans H99 at 1,335 CFU CFU/animal. Antifungal therapy with miltefosine (MTF) began
at 1 h following infection, while therapy with fluconazole (FLC) and amphotericin B (AMB) was initiated at 1 day postchallenge. Therapy with miltefosine at
doses of 1.8, 3.6, and 7.2 mg/kg (A) continued through day 4, and therapy with miltefosine at 15 and 45 mg/kg (B) or with fluconazole and amphotericin B (C)
continued through day 10 (n 10 mice per group). *, P 0.05 for median survival compared to untreated controls; §, P 0.05 for percent survival at study
endpoint compared to untreated controls.
FIG 3 Survival curves in mice inoculated intravenously with C. neoformansUSC1597 at 0.54 105 to 1.6 105 CFU/animal. In the monotherapy experiments
(A and B),miltefosine (MTF) began at 1 h postchallenge, while fluconazole (FLC) and amphotericin B (AMB)were initiated at 1 day postchallenge. Therapywith
miltefosine at doses of 1.8, 3.6, and 7.2 mg/kg continued through day 4, and therapy with miltefosine at 15 and 45 mg/kg, fluconazole, and amphotericin B
continued through day 10. For the combination therapy experiment (C), miltefosine at 45 mg/kg was combined with amphotericin B (n 10 mice per group).
*, P 0.05 for median survival compared to untreated controls; §, P 0.05 for percent survival at study endpoint compared to untreated controls.
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due toNaegleria fowleri (18, 25). The mechanism by which milte-
fosine inhibits fungi has also been elucidated. Following incorpo-
ration into Saccharomyces cerevisiae, miltefosine rapidly pene-
trates the mitochondrial inner membrane, where it inhibits
cytochrome c oxidase and disrupts membrane potential, leading
to apoptosis-like cell death (26).
Cryptococcalmeningoencephalitis is a commonmanifestation
of disseminated disease caused by C. neoformans, and there is a
clear need to develop new antifungal agents as well as to evaluate
available drugs for the treatment of this invasive mycosis; as such,
we sought to evaluate the efficacy of miltefosine in our established
murine model of this CNS infection. Based on the in vitro activity
that we observed and that reported by others, as well as previous
reports of in vivo efficacy, we expected to see benefitwith the use of
this agent. However, the results were negative in the majority of
our experiments as miltefosine monotherapy did not improve
survival in our animal models of cryptococcal meningoencepha-
litis or disseminated cryptococcosis caused by two different C.
neoformans isolates. In contrast, efficacy was observed with the
clinically available antifungals fluconazole and amphotericin B. In
addition, miltefosine failed to reduce fungal burden within the
brains or lungs of these animals and did not improve the effective-
ness of therapy when used in combination. The exact reason for
this lack of in vivo efficacy in our models is unclear as in vitro
activity was observed using the CLSI methodology for antifungal
susceptibility testing against yeasts. Furthermore, the MIC values
we observed against the two C. neoformans isolates were in agree-
ment with those reported by others (18). However, the in vitro
potency of this agent was significantly reduced when albumin was
added to the growthmedium.Miltefosine is highly protein bound
(95%) (27, 28), which could partially explain the lack of in vivo
activity we observed as there may be only a small fraction of un-
bound drug available to inhibit the organism at the site of infec-
tion. In addition, the effectiveness against disseminated crypto-
coccosis appeared to be dependent on the size of the infecting
inoculum as a trend toward improved survival was observedwhen
a lower inoculum was used to establish infection. The clinical
relevance of this finding is unknown, but it is noteworthy that
miltefosine lacked activity when mice were challenged with our
standard inocula in the cryptococcal meningoencephalitis and
disseminated cryptococcosis models, while the clinically available
agents fluconazole and amphotericin B remained effective.
A limitation of this study is that we did not evaluate the pharma-
cokinetics ofmiltefosine in these animalmodels, nor did we evaluate
different dosing strategies in an effort to potentially improve efficacy.
Thus, it is unknown whether effective concentrations were achieved
eitherwithin thebloodstreamorat the sitesof infection, including the
CNS.However, other investigators have reported favorable pharma-
cokinetics formiltefosine inmice and other animals, including good
oral bioavailability (82% to 95%), a long terminal half-life (range, 73
to 104 h), with extensive tissue distribution, including the brain (16,
29, 30). Inaddition,peakmiltefosine serumconcentrations above the
MICs for the two C. neoformans isolates used in our study and high
values for the area under the concentration-time curve (AUC) have
FIG 4 Survival curves in mice inoculated intravenously with C. neoformans H99 at 0.54  105 to 6.1  105 CFU/animal. Treatment with miltefosine (MTF)
began at 1 h postchallenge, while fluconazole (FLC) and amphotericin B (AMB) were started 1 day after infection. Therapy with miltefosine at doses of 1.8, 3.6,
and 7.2 mg/kg continued through day 4, and therapy with miltefosine at 15 and 45 mg/kg, fluconazole, and amphotericin B continued through day 10 (n 10
mice per group). *, P  0.05 for median survival compared to untreated controls; §, P  0.05 for percent survival at study endpoint compared to untreated
controls.
FIG 5 Survival curves in untreated mice challenged intravenously with C. neoformansH99 at different inoculum levels (A) or with a single inoculum (4.0 103
CFU/animal) and treated with miltefosine (MTF) (B). Miltefosine was initiated at 1 h postchallenge and continued through day 4 (n 10 mice per group).
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been reported in mice that received doses similar to those we tested
(29). Furthermore, in our initial experiment with miltefosine, acute
toxicity was observed in several mice following a single dose of 60
mg/kg. Thus, it is unlikely that the concentrations that we achieved
were suboptimal.
Although the results of this study donot eliminate the potential
utility of miltefosine for the treatment of invasive fungal infec-
tions, including those caused by Cryptococcus species, caution is
warranted. Additional concerns that may limit the clinical use of
this agent include dose-limiting side effects (i.e., nausea, vomiting,
and loss of appetite) reported in humans as well as the embryo-
toxic and teratogenic effects that have been observed in animals
(16). Further work is also needed in order to determine the poten-
tial role of miltefosine in the treatment of invasive mycoses prior
to the widespread clinical use of this agent.
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